Stock Market Live Updates: Sensex, Nifty Off Day’S Lows; Maruti, Tech Mahindra, Ultratech …

Stock Market LIVE Updates: Indian equity benchmarks Sensex and Nifty50 started Tuesday’s session on a positive note amid gains across most other Asian markets.

This could play into the hands of the BTC prices and we could see a possible upside in the token,” it said.

Paytm parent One97 Communications’ shares succumbed to selling pressure yet again, dropping below the Rs 1,100 mark on Tuesday.

Apart from that, the recent QIP of Rs 4,000 crore is helping it deleverage its balance sheet which is key when we evaluate some of these real estate players,” he said.

We have a target price of Rs 1,700 with an upside of about 35-37 percent from current levels,” he said.

Apart from that, the prices for the real estate sector have been pretty stagnant for last seven years and there has been a disciplined launch from the large players and that has led to kind of a balance between demand and supply,” he said.

“Post-pandemic, we saw demand pick up clearly and that led to an inventory overhang, which was one of the biggest concerns for the sector for the past couple of years.

Fabindia plans to raise more than Rs 4,000 crore through the proposed IPO, which is a combination of fresh issuance of equity and an offer for sale .

During market hours on Monday, UltraTech reported a net profit of Rs 1,710 crore for the October-December period, up 8 percent on a year-on-year basis.

It has been a roller coaster ride for the rupee for the last one month.

Manish Agarwal, CEO of Nazara Technologies, said in an interview to CNBC-TV18 that Datawrkz has strong revenue from the US, as 70 percent of its revenue comes from the US.

Taher Badshah, Chief Investment Officer-Equities at Invesco Mutual Fund, believes that one will see a better economic cycle unfold over the next couple of years, not just in India but across the globe.

On the other hand, Lupin and Laurus Labs were up 0.6 percent and 0.3 percent respectively.

Sun Pharma has been doing well as growth continues in the specialty segment, and specialty drugs are expected to continue to perform well for the company, he said.

…Read the full story